Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8A64W)

Drug Name
NP-118809 Drug Info
Synonyms
41332-24-5; NP118809; Z-160; 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone; UNII-TX3R141LEP; TX3R141LEP; CHEMBL604710; Piperazine, 1-(diphenylmethyl)-4-(1-oxo-3,3-diphenylpropyl)-; 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one; AC1NLRM8; GTPL7765; SCHEMBL4180792; CTK1D3910; DTXSID70407284; VCPMZDWBEWTGNW-UHFFFAOYSA-N; MolPort-001-545-055; EX-A2422; BCP08259; KS-00000T6R; ZINC20509316; 3934AH; STK411255; AKOS003297641; MK-6721; DB12743; MCULE-3294187169; CS-1361; API0014038; ACM41332245
Therapeutic ClassAnalgesics
Cross-matching ID
PubChem CID
4988454
ChEBI ID
CHEMBL604710
CAS Number
CAS 41332-24-5
TTD Drug ID
D06FSC

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
PPAR signaling pathway 2.33 0.00e+0 66/74 (89.19%) LPL;FABP4;SORBS1;...
Mineral absorption 1.93 1.06e-2 48/60 (80%) MT1E;MT1M;TF;...
Linoleic acid metabolism 1.75 4.87e-2 21/29 (72.41%) PLAAT3;CYP2C9;CYP3A4;...
ECM-receptor interaction 1.72 4.59e-2 80/88 (90.91%) ITGA6;CD36;ITGB4;...
Graft-versus-host disease -1.63 4.82e-2 32/42 (76.19%) HLA-DPB1;IL1B;HLA-F;...
Pathways of neurodegeneration -1.64 4.68e-2 354/475 (74.53%) PSMB6;MAPK10;CSNK2A2;...
Fructose and mannose metabolism -1.64 4.79e-2 30/33 (90.91%) FBP1;HKDC1;PFKL;...
Glyoxylate and dicarboxylate metabolism -1.67 4.30e-2 23/30 (76.67%) MMUT;MDH1;PCCB;...
Retrograde endocannabinoid signaling -1.67 4.39e-2 118/148 (79.73%) ADCY1;MAPK10;GABRG2;...
Pyruvate metabolism -1.70 3.12e-2 41/47 (87.23%) MDH1;PKM;ADH7;...
Alzheimer disease -1.77 1.14e-2 279/369 (75.61%) PSMB6;MAPK10;CSNK2A2;...
Steroid biosynthesis -1.78 1.22e-2 19/20 (95%) CYP51A1;SOAT1;LIPA;...
Thermogenesis -1.80 8.58e-3 173/232 (74.57%) ADCY7;ATP5MC2;PRKAB1;...
Huntington disease -1.82 7.66e-3 233/306 (76.14%) CREB5;COX6C;PSMB6;...
Rheumatoid arthritis -1.87 4.68e-3 78/93 (83.87%) CD28;ATP6V1E1;ATP6V0C;...
Parkinson disease -1.91 1.04e-3 176/249 (70.68%) NDUFS7;DDIT3;NDUFB11;...
Glycolysis / Gluconeogenesis -1.97 0.00e+0 56/67 (83.58%) AKR1A1;ENO2;ALDH3B1;...
IL-17 signaling pathway -2.02 0.00e+0 84/94 (89.36%) CXCL3;MUC5B;CXCL1;...
Prion disease -2.04 0.00e+0 209/273 (76.56%) CREB5;COX6C;PSMB6;...
Citrate cycle (TCA cycle) -2.11 0.00e+0 30/30 (100%) OGDH;DLST;IDH3B;...
Ribosome -2.12 0.00e+0 113/158 (71.52%) MRPS15;RPL6;RPS14;...
Diabetic cardiomyopathy -2.28 0.00e+0 162/203 (79.8%) PIK3R1;PPP1CA;ATP5MC2;...
Non-alcoholic fatty liver disease -2.35 0.00e+0 126/155 (81.29%) COX6C;MLXIP;MAPK10;...
Oxidative phosphorylation -2.85 0.00e+0 93/133 (69.92%) NDUFS7;NDUFB11;NDUFA10;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H